PMID- 20637128
OWN - NLM
STAT- MEDLINE
DCOM- 20110203
LR  - 20220410
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 10
DP  - 2010 Jul 19
TI  - Relationship between EGFR expression, copy number and mutation in lung 
      adenocarcinomas.
PG  - 376
LID - 10.1186/1471-2407-10-376 [doi]
AB  - BACKGROUND: This study was designed to investigate EGFR protein expression, EGFR 
      copy number and EGFR mutations in lung adenocarcinomas, to explore the 
      relationship of the three markers. METHODS: EGFR status was analyzed in 
      surgically resected lung adenocarcinoma samples from 133 Chinese patients by 
      three methods: protein expression (n=133) by standardized immunohistochemistry 
      (IHC), gene copy number (n=133) by fluorescence in situ hybridization (FISH), and 
      mutation analysis using the Scorpion amplification refractory mutation system 
      (ARMS) (n=133). RESULTS: The results showed that 68.4% of the samples were 
      positive by IHC, 42.1% were positive by FISH, and 63.9% contained activating 
      kinase domain mutations. EGFR mutations were more frequent in non-smoking 
      patients (p=0.008), and EGFR mutations were associated with EGFR FISH positivity 
      (p<0.0001). When using 10% positivity and 2+ as cutoffs, EGFR protein expression 
      was significantly correlated with EGFR FISH positivity (p=0.012) and EGFR 
      mutations (p=0.008) after Bonferroni correction. CONCLUSION: EGFR protein 
      expression, EGFR copy number and EGFR mutations were closely related to each 
      other. Standard methods and interpretation criteria need to be established.
FAU - Liang, Zhiyong
AU  - Liang Z
AD  - Department of Pathology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Science, Beijng 100730, China.
FAU - Zhang, Jing
AU  - Zhang J
FAU - Zeng, Xuan
AU  - Zeng X
FAU - Gao, Jie
AU  - Gao J
FAU - Wu, Shafei
AU  - Wu S
FAU - Liu, Tonghua
AU  - Liu T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100719
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Adenocarcinoma/genetics/metabolism/secondary
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/*metabolism/secondary
MH  - DNA Mutational Analysis
MH  - ErbB Receptors/*genetics/*metabolism
MH  - Female
MH  - *Gene Dosage
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/genetics/metabolism/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Mutation/*genetics
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Survival Rate
PMC - PMC2913962
EDAT- 2010/07/20 06:00
MHDA- 2011/02/04 06:00
PMCR- 2010/07/19
CRDT- 2010/07/20 06:00
PHST- 2009/12/24 00:00 [received]
PHST- 2010/07/19 00:00 [accepted]
PHST- 2010/07/20 06:00 [entrez]
PHST- 2010/07/20 06:00 [pubmed]
PHST- 2011/02/04 06:00 [medline]
PHST- 2010/07/19 00:00 [pmc-release]
AID - 1471-2407-10-376 [pii]
AID - 10.1186/1471-2407-10-376 [doi]
PST - epublish
SO  - BMC Cancer. 2010 Jul 19;10:376. doi: 10.1186/1471-2407-10-376.